BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16205037)

  • 1. [Drug-drug interaction of antifungal drugs].
    Niwa T; Shiraga T; Takagi A
    Yakugaku Zasshi; 2005 Oct; 125(10):795-805. PubMed ID: 16205037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450.
    Niwa T; Imagawa Y; Yamazaki H
    Curr Drug Metab; 2014; 15(7):651-79. PubMed ID: 25429674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.
    Niwa T; Shiraga T; Takagi A
    Biol Pharm Bull; 2005 Sep; 28(9):1805-8. PubMed ID: 16141567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs.
    Sakaeda T; Iwaki K; Kakumoto M; Nishikawa M; Niwa T; Jin JS; Nakamura T; Nishiguchi K; Okamura N; Okumura K
    J Pharm Pharmacol; 2005 Jun; 57(6):759-64. PubMed ID: 15969931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes.
    Niwa T; Inoue-Yamamoto S; Shiraga T; Takagi A
    Biol Pharm Bull; 2005 Sep; 28(9):1813-6. PubMed ID: 16141569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole.
    Hyland R; Jones BC; Smith DA
    Drug Metab Dispos; 2003 May; 31(5):540-7. PubMed ID: 12695341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.
    Venkatakrishnan K; von Moltke LL; Greenblatt DJ
    Clin Pharmacokinet; 2000 Feb; 38(2):111-80. PubMed ID: 10709776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients.
    Laverdiere M; Hoban D; Restieri C; Habel F
    J Antimicrob Chemother; 2002 Jul; 50(1):119-23. PubMed ID: 12096017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
    Gilgado F; Serena C; Cano J; Gené J; Guarro J
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4211-3. PubMed ID: 17015631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data.
    Nakasa H; Nakamura H; Ono S; Tsutsui M; Kiuchi M; Ohmori S; Kitada M
    Eur J Clin Pharmacol; 1998 Apr; 54(2):177-83. PubMed ID: 9626925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.
    Jeong S; Nguyen PD; Desta Z
    Antimicrob Agents Chemother; 2009 Feb; 53(2):541-51. PubMed ID: 19029318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of cytochrome P450 gene polymorphism in a lupus nephritis patient in whom tacrolimus blood concentration was markedly elevated after administration of azole antifungal agents.
    Fujita Y; Araki T; Okada Y; Aomori T; Shimizu R; Tomizawa T; Hiromura K; Nojima Y; Nakamura T; Yamamoto K
    J Clin Pharm Ther; 2013 Feb; 38(1):74-6. PubMed ID: 22971159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro interactions of micafungin with other antifungal drugs against clinical isolates of four species of Cryptococcus.
    Serena C; Fernández-Torres B; Pastor FJ; Trilles L; Lazéra Mdos S; Nolard N; Guarro J
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2994-6. PubMed ID: 15980382
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.
    Chiou CC; Groll AH; Walsh TJ
    Oncologist; 2000; 5(2):120-35. PubMed ID: 10794803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of cytochromes P450 by antifungal imidazole derivatives.
    Zhang W; Ramamoorthy Y; Kilicarslan T; Nolte H; Tyndale RF; Sellers EM
    Drug Metab Dispos; 2002 Mar; 30(3):314-8. PubMed ID: 11854151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous exophiala species.
    Najafzadeh MJ; Saradeghi Keisari M; Vicente VA; Feng P; Shamsian SA; Rezaei-Matehkolaei A; de Hoog GS; Curfs-Breuker I; Meis JF
    Antimicrob Agents Chemother; 2013 Dec; 57(12):6395-8. PubMed ID: 24100491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
    Nguyen MH; Yu CY
    J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults.
    Keirns J; Sawamoto T; Holum M; Buell D; Wisemandle W; Alak A
    Antimicrob Agents Chemother; 2007 Feb; 51(2):787-90. PubMed ID: 17116670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
    Mario DA; Denardi LB; Bandeira LA; Antunes MS; Santurio JM; Severo LC; Alves SH
    Mem Inst Oswaldo Cruz; 2012 May; 107(3):433-6. PubMed ID: 22510843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.